23/06/2026
PRESS RELEASE: Press Release: Sanofi’s (tolebrutinib) approved in the EU (European Union) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses.
Read: https://bit.ly/44uGZME
Sanofi US
-----------